Network-guided prediction of aromatase inhibitor response in breast cancer

Prediction of response to specific cancer treatments is complicated by significant heterogeneity between tumors in terms of mutational profiles, gene expression, and clinical measures. Here we focus on the response of Estrogen Receptor (ER)+ post-menopausal breast cancer tumors to aromatase inhibitors (AI). We use a network smoothing algorithm to learn novel features that integrate several types of high throughput data and new cell line experiments. These features greatly improve the ability to predict response to AI when compared to prior methods. For a subset of the patients, for which we obtained more detailed clinical information, we can further predict response to a specific AI drug.

[1]  Mousumi Banerjee,et al.  The role of pancreatic stellate cells in pancreatic disorders , 2016 .

[2]  M. Ellis.  Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. , 2017, Breast.

[3]  Marina Vannucci,et al.  A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. , 2018, Biostatistics.

[4]  Jinyu Chen,et al.  Discovery of two-level modular organization from matched genomic data via joint matrix tri-factorization , 2018, Nucleic acids research.

[5]  Matthew Ruffalo,et al.  Whole-exome sequencing enhances prognostic classification of myeloid malignancies , 2015, J. Biomed. Informatics.

[6]  Adam B. Olshen,et al.  Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..

[7]  J. Clements,et al.  Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.

[8]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[9]  Jung Eun Shim,et al.  TRRUST: a reference database of human transcriptional regulatory interactions , 2015, Scientific Reports.

[10]  S. Sleijfer,et al.  An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients , 2016, BMC Cancer.

[11]  D. Dabbs,et al.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. , 2014, Cancer research.

[12]  Benjamin J. Raphael,et al.  A weighted exact test for mutually exclusive mutations in cancer , 2016, Bioinform..

[13]  A. D’Andrea,et al.  A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy , 2012, Journal of the National Cancer Institute.

[14]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[15]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[16]  T. Sellers,et al.  Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. , 2013, Journal of the National Cancer Institute.

[17]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[18]  Jorge S. Reis-Filho,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[19]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[20]  Roded Sharan,et al.  Network-Based Integration of Disparate Omic Data To Identify "Silent Players" in Cancer , 2015, PLoS Comput. Biol..

[21]  J. Diehl.  Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.

[22]  Bernhard Schölkopf,et al.  Learning with Local and Global Consistency , 2003, NIPS.

[23]  Aung Ko Win,et al.  KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers , 2013, British Journal of Cancer.

[24]  E. Flemington,et al.  miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling , 2014, Genes & cancer.

[25]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[26]  J. V. D. van der Hoeven,et al.  Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. , 2015, Cancer treatment reviews.

[27]  Baolin Wu,et al.  Network-based Survival Analysis Reveals Subnetwork Signatures for Predicting Outcomes of Ovarian Cancer Treatment , 2013, PLoS Comput. Biol..

[28]  Martin H. Schaefer,et al.  HIPPIE v2.0: enhancing meaningfulness and reliability of protein–protein interaction networks , 2016, Nucleic Acids Res..

[29]  I. Beavon.  The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. , 2000, European journal of cancer.

[30]  J. Olson,et al.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Niko Beerenwinkel,et al.  Modeling Mutual Exclusivity of Cancer Mutations , 2014, RECOMB.

[32]  J. Clements,et al.  Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.

[33]  F. Pontén,et al.  O-014High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort , 2015 .

[34]  Christopher A. Miller,et al.  Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation , 2016, Nature Communications.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[36]  Lei Liu,et al.  Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis , 2015, OncoTargets and therapy.

[37]  Andrew D. Rouillard,et al.  LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures , 2014, Nucleic Acids Res..

[38]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[39]  Ethem Alpaydin,et al.  Multiple Kernel Learning Algorithms , 2011, J. Mach. Learn. Res..

[40]  Paul J van Diest,et al.  c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. , 2006, Human pathology.

[41]  M. Dowsett,et al.  Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[43]  M. Dowsett,et al.  miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. , 2016, Cancer research.

[44]  Roded Sharan,et al.  Associating Genes and Protein Complexes with Disease via Network Propagation , 2010, PLoS Comput. Biol..

[45]  L. Feng,et al.  Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2). , 2014, Gene.

[46]  Ron Bose,et al.  HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.

[47]  Adrian V. Lee,et al.  Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.

[48]  Fabio Massimo Zanzotto,et al.  RISK: A Random Optimization Interactive System Based on Kernel Learning for Predicting Breast Cancer Disease Progression , 2017, IWBBIO.

[49]  Nico Pfeifer,et al.  Integrating different data types by regularized unsupervised multiple kernel learning with application to cancer subtype discovery , 2015, Bioinform..

[50]  M. Loda,et al.  Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer , 2004, Cancer Research.

[51]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[52]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[53]  Martin H. Schaefer,et al.  HIPPIE: Integrating Protein Interaction Networks with Experiment Based Quality Scores , 2012, PloS one.

[54]  Riccardo Bellazzi,et al.  A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer , 2016, PloS one.

[55]  R. Pestell,et al.  Examining the role of cyclin D1 in breast cancer. , 2011, Future oncology.

[56]  S. Berger,et al.  A rare DNA contact mutation in cancer confers p53 gain‐of‐function and tumor cell survival via TNFAIP8 induction , 2016, Molecular oncology.

[57]  Kenta Nakai,et al.  Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses , 2018, Scientific Reports.

[58]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[59]  J. Geisler,et al.  Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? , 2011, British Journal of Cancer.

[60]  Ivan G. Costa,et al.  A multiple kernel learning algorithm for drug-target interaction prediction , 2016, BMC Bioinformatics.

[61]  P. Lønning,et al.  Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved , 2013, Endocrine-related cancer.

[62]  Zhuowen Tu,et al.  Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.

[63]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[64]  M. Dowsett,et al.  Early Surrogate Markers of Treatment Activity: Where Are We Now? , 2015, Journal of the National Cancer Institute. Monographs.

[65]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[66]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.